NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

The American Brain Tumor Association cites that there is an average of 27% of GBM patients treated on standard of care that live to 2 years.

For adults with the more aggressive glioblastoma, treated with concurrent temozolomide and radiation therapy, median survival is about 14.6 months with a two-year median survival rate of 27%;

https://2knaef3o0jpz4ff42k23tr6l-wpengine.netdna-ssl.com/wp-content/uploads/2018/03/glioblastoma-brochure.pdf

In February 2018, it was reported that early studies using oncolytic virus therapy showed 20% of GBM patients were still alive at 3 years or longer after treatment.

At a February 2018 brain cancer immunotherapy conference Dr. Okada helped organize, several research groups reported similar results from small trials of oncolytic viruses. In these early studies, approximately 20% of patients with glioblastoma were still alive 3 years or longer after treatment.

https://www.cancer.gov/news-events/cancer-currents-blog/2018/immunotherapy-glioblastoma

So your cited 26.8% of the "correct 'actual'" numbers for DCVax-L of 26.8% would be even better than what Dr. Okada thought as promising.

And if we go with 91/331 (instead of 88), the percentage from LL's talk rises to 27.5%. And let's remember, that includes over 30 control patients who never even received DCVax.

I doubt those percentages overall could be accorded to chance or other improvements in care, or we'd be seeing those type of results everywhere.